Patent 9688714 was granted and assigned to Epizyme on June, 2017 by the United States Patent and Trademark Office.
The present invention relates to substituted purine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.